Evidence map›Paper›PMID 38506812›Full record

ArticleJAMA network open2024

Adrenal-Permissive HSD3B1 Genotype-An Invisible Stimulator of Prostate Cancer Mortality.

Lina Schiffer, Nima Sharifi

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Serendipity, steroids and science.The Journal of steroid biochemistry and molecular biology · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Lina SchifferDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida.
Nima SharifiDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida.

Funding

Elucidating a novel molecular biomarker for castration-resistant prostate cancerR01CA172382 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Nima Sharifi · 2012 to 2026
$5.2M
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate CancerR01CA249279 · NCI · UNIVERSITY OF MINNESOTA · PI HALABI, SUSAN, SHARIFI, NIMA · 2021 to 2024
$2.1M
Compensatory steroidogenesis mechanisms in castration-resistant prostate cancerR01CA190289 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SHARIFI, NIMA · 2015 to 2019
$2.1M
Aberrant tumor metabolism that enables AR antagonist-resistant prostate cancerR01CA236780 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SHARIFI, NIMA · 2020 to 2024
$1.8M
CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapyR01CA261995 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Nima Sharifi · 2022 to 2026
$1.8M
Cooperative steroidogenic inhibition for treatment of advanced prostate cancerR01CA168899 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SHARIFI, NIMA · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA168899NCI NIH HHS R01 CA172382NCI NIH HHS R01 CA190289NCI NIH HHS R01 CA236780NCI NIH HHS R01 CA249279NCI NIH HHS R01 CA261995
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic NeoplasmsGenotypeHumansMaleMultienzyme ComplexesProstateMultienzyme Complexes

Identifiers

PMID38506812
PMCPMC11500769

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.